Hanie Ranaei, V. Raeesi, Fatemeh Salmani, Soroush Khojasteh-Kaffash, Z. Saremi
Introduction: One of the major public health problems is end-stage renal disease (ESRD). ESRD is commonly associated with musculoskeletal disorders (MSDs). Objectives: Due to the importance of MSDs in hemodialysis patients and the absence of sufficient studies in Iran, this study aims to investigate MSDs in hemodialysis patients. Patients and Methods: This cross-sectional study was conducted on 75 patients with ESRD, who were under hemodialysis at the special diseases center of Birjand university of medical sciences, south Khorasan, Iran. Inclusion criteria were history of at least 2 years of hemodialysis, and age more than 18 years. All patients with previous neurological disorders, previous rheumatic diseases, previous arthroplasty of the limbs, and severe psychological disorders were excluded from the study. Baseline characteristics and laboratory data collected. MSDs examined based on the Nordic Musculoskeletal Screening Questionnaire (NMQ). Data were described using central tendency, CHI-SQUARE test, and Fisher’s exact test were used. The significance level in this study was P<0.05. Results: Seventy-five patients participated (Mean and standard deviation (SD) of age: 62.13±1.73 years, male to female ratio: 1.14). Sixty-three patients (84.0%) had MSDs. There was no significant difference based on age, dialysis vintage, gender, laboratory tests, and comorbidities (P>0.05). Dialysis etiology, knee osteoarthritis, shins pain, knee pain and knee range of motion had significantly difference between groups (respectively, P=0.047, P=0.003, P=0.012, P=0.001, P=0.002). Conclusion: The frequency of MSDs in these patients was 84.0%. There was a significant association between MSDs with the cause of hemodialysis, lower limb pain, and knee osteoarthritis.
{"title":"Musculoskeletal disorders in hemodialysis patients: prevalence, clinical symptoms, and associated factors","authors":"Hanie Ranaei, V. Raeesi, Fatemeh Salmani, Soroush Khojasteh-Kaffash, Z. Saremi","doi":"10.34172/npj.2023.11656","DOIUrl":"https://doi.org/10.34172/npj.2023.11656","url":null,"abstract":"Introduction: One of the major public health problems is end-stage renal disease (ESRD). ESRD is commonly associated with musculoskeletal disorders (MSDs). Objectives: Due to the importance of MSDs in hemodialysis patients and the absence of sufficient studies in Iran, this study aims to investigate MSDs in hemodialysis patients. Patients and Methods: This cross-sectional study was conducted on 75 patients with ESRD, who were under hemodialysis at the special diseases center of Birjand university of medical sciences, south Khorasan, Iran. Inclusion criteria were history of at least 2 years of hemodialysis, and age more than 18 years. All patients with previous neurological disorders, previous rheumatic diseases, previous arthroplasty of the limbs, and severe psychological disorders were excluded from the study. Baseline characteristics and laboratory data collected. MSDs examined based on the Nordic Musculoskeletal Screening Questionnaire (NMQ). Data were described using central tendency, CHI-SQUARE test, and Fisher’s exact test were used. The significance level in this study was P<0.05. Results: Seventy-five patients participated (Mean and standard deviation (SD) of age: 62.13±1.73 years, male to female ratio: 1.14). Sixty-three patients (84.0%) had MSDs. There was no significant difference based on age, dialysis vintage, gender, laboratory tests, and comorbidities (P>0.05). Dialysis etiology, knee osteoarthritis, shins pain, knee pain and knee range of motion had significantly difference between groups (respectively, P=0.047, P=0.003, P=0.012, P=0.001, P=0.002). Conclusion: The frequency of MSDs in these patients was 84.0%. There was a significant association between MSDs with the cause of hemodialysis, lower limb pain, and knee osteoarthritis.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139310132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Dapoxetine is a novel therapeutic agent employed in treating specific diseases. However, its potential impact on renal excretion processes has yet to be thoroughly investigated, necessitating further exploration in this study. Objectives: This research aimed to assess the effects of dapoxetine on renal function and explore any potential disturbances in kidney excretion processes. Materials and Methods: In this study, 32 male Albino rats weighing between 200-250 g were utilized. The rats were randomly divided into four groups. Group one served as the control and received a normal diet, while groups two to four were administered dapoxetine through gavage at doses of 1 mg/kg, 2 mg/kg, and 4 mg/kg, respectively. The study evaluated blood urea nitrogen (BUN), and serum creatinine levels and examined renal pathological changes in the rats. Results: The results demonstrated a significant increase in average BUN levels in group four compared to other groups (P<0.001). For creatinine, group three displayed higher levels compared to other groups. However, the difference was not statistically significant (P>0.05). Importantly, no indications of apoptosis, necrosis, edema, hydropic degeneration, or glomerular changes were observed in any of the renal cells from the rat groups. Conclusion: Dapoxetine administration led to changes in BUN and creatinine levels; however, it did not adversely affect the renal cells’ pathological outcomes. These results suggest that dapoxetine could be considered for use in the future treatment of certain diseases, considering its minimal impact on renal function. Further investigations and clinical trials are warranted to corroborate these findings and inform medical decision-making.
{"title":"Investigation of the effects of oral dapoxetine on kidney function and histopathologic changes in male rats; an animal study and future perspectives","authors":"Alireza Akhavan Rezayat, Amirabbas Asadpour, Samaneh Boroumand-Noughabi, M. Kabiri, Elham Ghafarian Baghaei Moghadam, Alireza Nough Javazm","doi":"10.34172/npj.2023.10633","DOIUrl":"https://doi.org/10.34172/npj.2023.10633","url":null,"abstract":"Introduction: Dapoxetine is a novel therapeutic agent employed in treating specific diseases. However, its potential impact on renal excretion processes has yet to be thoroughly investigated, necessitating further exploration in this study. Objectives: This research aimed to assess the effects of dapoxetine on renal function and explore any potential disturbances in kidney excretion processes. Materials and Methods: In this study, 32 male Albino rats weighing between 200-250 g were utilized. The rats were randomly divided into four groups. Group one served as the control and received a normal diet, while groups two to four were administered dapoxetine through gavage at doses of 1 mg/kg, 2 mg/kg, and 4 mg/kg, respectively. The study evaluated blood urea nitrogen (BUN), and serum creatinine levels and examined renal pathological changes in the rats. Results: The results demonstrated a significant increase in average BUN levels in group four compared to other groups (P<0.001). For creatinine, group three displayed higher levels compared to other groups. However, the difference was not statistically significant (P>0.05). Importantly, no indications of apoptosis, necrosis, edema, hydropic degeneration, or glomerular changes were observed in any of the renal cells from the rat groups. Conclusion: Dapoxetine administration led to changes in BUN and creatinine levels; however, it did not adversely affect the renal cells’ pathological outcomes. These results suggest that dapoxetine could be considered for use in the future treatment of certain diseases, considering its minimal impact on renal function. Further investigations and clinical trials are warranted to corroborate these findings and inform medical decision-making.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139312596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gestational diabetes mellitus (GDM) is a complication of pregnancy defined as any level of early or first detection of glucose intolerance in pregnancy. It is a prevalent metabolic disorder associated with several maternal and neonatal complications. On the other hand, chronic kidney disease is a leading cause of premature morbidity and mortality worldwide, and diabetic nephropathy accounts for approximately half of all cases of end-stage renal disease. Due to these two conditions’ high prevalence and significance, any possible association would be a public health concern requiring further investigation. To this end, the current study aimed to review the adverse effects of GDM on maternal and neonatal kidneys.
{"title":"The adverse effects of gestational diabetes mellitus on maternal and neonatal kidneys","authors":"Afagh Hassanzadeh Rad, Niloufar Nazeri","doi":"10.34172/npj.2023.10632","DOIUrl":"https://doi.org/10.34172/npj.2023.10632","url":null,"abstract":"Gestational diabetes mellitus (GDM) is a complication of pregnancy defined as any level of early or first detection of glucose intolerance in pregnancy. It is a prevalent metabolic disorder associated with several maternal and neonatal complications. On the other hand, chronic kidney disease is a leading cause of premature morbidity and mortality worldwide, and diabetic nephropathy accounts for approximately half of all cases of end-stage renal disease. Due to these two conditions’ high prevalence and significance, any possible association would be a public health concern requiring further investigation. To this end, the current study aimed to review the adverse effects of GDM on maternal and neonatal kidneys.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135966744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cancer in IgA nephropathy; a letter to the editor on current findings","authors":"Maryam Alem, Mahoor Abedzadeh, Zahra Golestani Hotkani, Parham Mashouf, Neda Kianpour, Leila Alem","doi":"10.34172/npj.2023.10642","DOIUrl":"https://doi.org/10.34172/npj.2023.10642","url":null,"abstract":"<jats:p> </jats:p>","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135966746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucidated. The high cost of eculizumab therapy and the rare adverse effects have created a paradox in conducting large clinical trials. Therefore, there is a need to increase clinicians’ awareness of the available data on the efficacy/safety of this drug in treating renal diseases. Herein, we have reviewed the outcomes of the administration of eculizumab in aHUS, PNH, lupus erythematosus nephritis, C3 glomerulonephritis, IgA nephropathy, and antibody-mediated rejection (AMR) in highly sensitized patients. Initial findings suggest its efficacy in treating acute injuries but lower effectiveness in preventing chronic lesions. Besides, early diagnosis and timely initiation of eculizumab are of particular importance.
{"title":"Eculizumab in kidney diseases","authors":"F. Pour-Reza-Gholi, S. Assadiasl","doi":"10.34172/npj.2023.10630","DOIUrl":"https://doi.org/10.34172/npj.2023.10630","url":null,"abstract":"The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucidated. The high cost of eculizumab therapy and the rare adverse effects have created a paradox in conducting large clinical trials. Therefore, there is a need to increase clinicians’ awareness of the available data on the efficacy/safety of this drug in treating renal diseases. Herein, we have reviewed the outcomes of the administration of eculizumab in aHUS, PNH, lupus erythematosus nephritis, C3 glomerulonephritis, IgA nephropathy, and antibody-mediated rejection (AMR) in highly sensitized patients. Initial findings suggest its efficacy in treating acute injuries but lower effectiveness in preventing chronic lesions. Besides, early diagnosis and timely initiation of eculizumab are of particular importance.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49165356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Sari, Yanis Kartini, Imamatul Faizah, Riska Rohmawati, Siti Nur Hasina
Introduction: In hemodialysis patients, the main problem that often occurs is experiencing fatigue. Untreated fatigue conditions have an impact on decreasing quality of life. Objectives: In this study, we aimed to analyse the effect of the combination of AROM with deep breathing on fatigue and quality of life in the Jemursari Islamic hospital of Surabaya. Patients and Methods: This study is a quasi-experimental investigation with a pre-post-test control group design. The population was 244 of all hemodialysis patients at our hospital. The research sample was 220 respondents, 110 respondents in the intervention group and the control group. The intervention group was given a combination of active range of motion (AROM) and deep breathing exercises for 30 minutes daily for one month. Meanwhile, the control group was assigned training according to hospital procedures. Results: The results showed that almost all of the intervention group (96.4%) had mild fatigue and almost half (40%) had good quality of life. In the control group, most participants (54.5%) experienced severe fatigue, and most (53.6%) experienced a poor quality of life. Data analysis showed that the combination of AROM with deep breathing affected hemodialysis patients’ fatigue and quality of life (P =0.000), which means that the combination of AROM with deep breathing affects the fatigue and quality of life of hemodialysis patients. Conclusion: A combination of air exercise regularly can reduce fatigue levels and improve quality of life. Nurses can provide a combination of AROM with deep breathing exercises in hemodialysis patients as an exercise program for hemodialysis patients.
{"title":"Combination of AROM with deep breathing exercise against fatigue and quality of life of hemodialysis patients; an experimental study","authors":"R. Sari, Yanis Kartini, Imamatul Faizah, Riska Rohmawati, Siti Nur Hasina","doi":"10.34172/npj.2023.10551","DOIUrl":"https://doi.org/10.34172/npj.2023.10551","url":null,"abstract":"Introduction: In hemodialysis patients, the main problem that often occurs is experiencing fatigue. Untreated fatigue conditions have an impact on decreasing quality of life. Objectives: In this study, we aimed to analyse the effect of the combination of AROM with deep breathing on fatigue and quality of life in the Jemursari Islamic hospital of Surabaya. Patients and Methods: This study is a quasi-experimental investigation with a pre-post-test control group design. The population was 244 of all hemodialysis patients at our hospital. The research sample was 220 respondents, 110 respondents in the intervention group and the control group. The intervention group was given a combination of active range of motion (AROM) and deep breathing exercises for 30 minutes daily for one month. Meanwhile, the control group was assigned training according to hospital procedures. Results: The results showed that almost all of the intervention group (96.4%) had mild fatigue and almost half (40%) had good quality of life. In the control group, most participants (54.5%) experienced severe fatigue, and most (53.6%) experienced a poor quality of life. Data analysis showed that the combination of AROM with deep breathing affected hemodialysis patients’ fatigue and quality of life (P =0.000), which means that the combination of AROM with deep breathing affects the fatigue and quality of life of hemodialysis patients. Conclusion: A combination of air exercise regularly can reduce fatigue levels and improve quality of life. Nurses can provide a combination of AROM with deep breathing exercises in hemodialysis patients as an exercise program for hemodialysis patients.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48108007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic kidney disease (CKD) patients are need to do kidney functioning tests in a regular interval due to this time money as well as energy are affected. This study determines the difference of standard deviation of the patient’s weight, systolic blood pressure (BP) and diastolic BP pre- and post-dialysis and observe the changes that takes place in the patients’ health. Moreover, as the kidney functioning tests are time consuming and expensive, therefore in order to save time and money we want to give a mathematical solution for the benefit of mankind. The data of the CKD patients has been collected from medical college and hospital, Assam. The data collection was done randomly selecting 5 CKD patients and the data comprises of the body weight, BP of the patient pre dialysis and post dialysis. Analysis the data with some statistical tools (standard deviation, σ) and interpret the result. The difference of standard deviation of the patient’s weight, BP of systolic and diastolic are measure pre and post dialysis, it is found either the patient is approaching towards good health or not.
{"title":"A mathematical analysis of dialysis report and kidney function tests; a case study","authors":"A. Barhoi","doi":"10.34172/npj.2023.10600","DOIUrl":"https://doi.org/10.34172/npj.2023.10600","url":null,"abstract":"Chronic kidney disease (CKD) patients are need to do kidney functioning tests in a regular interval due to this time money as well as energy are affected. This study determines the difference of standard deviation of the patient’s weight, systolic blood pressure (BP) and diastolic BP pre- and post-dialysis and observe the changes that takes place in the patients’ health. Moreover, as the kidney functioning tests are time consuming and expensive, therefore in order to save time and money we want to give a mathematical solution for the benefit of mankind. The data of the CKD patients has been collected from medical college and hospital, Assam. The data collection was done randomly selecting 5 CKD patients and the data comprises of the body weight, BP of the patient pre dialysis and post dialysis. Analysis the data with some statistical tools (standard deviation, σ) and interpret the result. The difference of standard deviation of the patient’s weight, BP of systolic and diastolic are measure pre and post dialysis, it is found either the patient is approaching towards good health or not.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139364515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Rastegar-Kashkouli, Mohsen Jafari, Saina Karami, Pourya Yousefi, A. Taravati, Ashkan Khavaran, Dordaneh Rastegar, Mohammad Reza Jafari, Seyedeh Yasaman Alemohammad, Ghader Dargahi Abbasabad, Mohammad Shahbaz, Mohammad Ebrahimi Kalan
Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.
{"title":"Association between type 2 diabetes mellitus and multiple myeloma: Fact or fiction","authors":"Ali Rastegar-Kashkouli, Mohsen Jafari, Saina Karami, Pourya Yousefi, A. Taravati, Ashkan Khavaran, Dordaneh Rastegar, Mohammad Reza Jafari, Seyedeh Yasaman Alemohammad, Ghader Dargahi Abbasabad, Mohammad Shahbaz, Mohammad Ebrahimi Kalan","doi":"10.34172/npj.2023.10604","DOIUrl":"https://doi.org/10.34172/npj.2023.10604","url":null,"abstract":"Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43984735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Toumaj, S. Alimohammadi, Maryam Ghasemi, Shokouh Shayanpour
Immunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one of the main causes of renal failure. Systemic corticosteroid therapy may protect against renal deterioration in IgA nephropathy; however, it is not often advised for long-term treatment due to possible side effects. Recent studies present promising results of the new targeted-release formulation of budesonide that delivers the drug to the distal ileum to reduce side effects for patients with IgA nephropathy. In this paper, we highlighted the potential benefits of budesonide as a treatment option for IgA nephropathy and the need for additional studies to confirm its effectiveness. The lack of alternative treatments to prevent renal deterioration without other systemic side effects motivated us to gather relevant information to fill this gap. In this brief overview, we have reviewed some of the most recently published studies regarding how budesonide protects against IgA nephropathy. Studies reveal that budesonide might significantly decrease proteinuria, hematuria, and creatinine level while maintaining normal renal function. Though, a limited number of trials have been established to date, and further investigations are needed to confirm the benefit of the new targeted-release budesonide in treating IgA nephropathy.
{"title":"Targeted-release budesonide in immunoglobulin A nephropathy; a mini-review","authors":"S. Toumaj, S. Alimohammadi, Maryam Ghasemi, Shokouh Shayanpour","doi":"10.34172/npj.2023.10605","DOIUrl":"https://doi.org/10.34172/npj.2023.10605","url":null,"abstract":"Immunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one of the main causes of renal failure. Systemic corticosteroid therapy may protect against renal deterioration in IgA nephropathy; however, it is not often advised for long-term treatment due to possible side effects. Recent studies present promising results of the new targeted-release formulation of budesonide that delivers the drug to the distal ileum to reduce side effects for patients with IgA nephropathy. In this paper, we highlighted the potential benefits of budesonide as a treatment option for IgA nephropathy and the need for additional studies to confirm its effectiveness. The lack of alternative treatments to prevent renal deterioration without other systemic side effects motivated us to gather relevant information to fill this gap. In this brief overview, we have reviewed some of the most recently published studies regarding how budesonide protects against IgA nephropathy. Studies reveal that budesonide might significantly decrease proteinuria, hematuria, and creatinine level while maintaining normal renal function. Though, a limited number of trials have been established to date, and further investigations are needed to confirm the benefit of the new targeted-release budesonide in treating IgA nephropathy.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49522982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Implication for health policy/practice/research/medical education: Sodium-glucose cotransporter-2 inhibitors is a promising treatment option for patients with diabetes-associated renal dysfunction.
{"title":"Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy","authors":"S. Zandifar, Shokouh Shayanpour","doi":"10.34172/npj.2023.10606","DOIUrl":"https://doi.org/10.34172/npj.2023.10606","url":null,"abstract":"Implication for health policy/practice/research/medical education: Sodium-glucose cotransporter-2 inhibitors is a promising treatment option for patients with diabetes-associated renal dysfunction.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49374748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：